報告摘要

Pharmaceutical Intermediate CDMO Market Research Report by Type of Intermediate [Active Pharmaceutical Ingredients (APIs), Excipients and Additives, Biologics Intermediates, Nucleotide Intermediates], by Drug Type (Generic Drugs, Branded Drugs), by Application (Oncology, Cardiovascular Diseases, CNS & Neurological Disorders, Infectious Diseases), and by Region (North America, Europe, South America, Middle East and Africa, and Asia Pacific) Forecast till 2035 Market Overview From 2024 to 2035, the global pharmaceutical intermediate CDMO market is projected to increase at a compound annual growth rate (CAGR) of 7.4% to reach USD 346,744.3 million. In 2024, the market was valued at USD 161,798.9 million. The global Pharmaceutical Intermediate CDMO (Contract Development and Manufacturing Organization) market is witnessing strong growth driven by several factors. Pharmaceutical companies are increasingly outsourcing intermediate manufacturing to CDMOs to streamline operations and cut costs. The rising demand for generic drugs and biosimilars, particularly in developing regions, is significantly boosting market expansion. Additionally, rapid technological advancements in intermediate synthesis and the increasing complexity of drug molecules are encouraging companies to rely on specialized CDMO services. Emerging markets are also playing a vital role in global growth due to favorable government policies and rising healthcare infrastructure. The market faces restraints such as stringent regulatory frameworks and complex approval processes, which can delay product timelines. High operational and capital costs, IP protection concerns, and raw material shortages also pose challenges. Moreover, there’s a lack of skilled expertise in niche chemistries. Nonetheless, opportunities lie in forming strategic collaborations with biotech firms and capitalizing on the rising trend of personalized medicine. Market Segmentations Global Pharmaceutical intermediate CDMO market has been segmented by type of intermediate, includes active pharmaceutical ingredients (APIS), excipients and additives, biologics intermediates, nucleotide intermediates. In terms of drug type, the global market is divided into generic drugs, branded drug. Based on the application types, global pharmaceutical intermediate CDMO market comprises oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease. The market is categorized into region, includes North America, Europe, South America, Middle East and Africa, and Asia Pacific. Regional Insights North America leads the global pharmaceutical intermediate CDMO market, with the U.S. at the forefront due to its advanced technology, substantial R&D funding, and strict FDA regulations. Canada’s growing biopharma industry also adds to the region’s strength. In Europe, the market caters to both local and international pharmaceutical firms, focusing on innovation, compliance, and high-quality solutions for complex chemical syntheses. The adoption of eco-friendly practices and support for circular economy initiatives are transforming manufacturing approaches. Asia Pacific stands out as the fastest-growing region, mainly fueled by China and India's affordable production capacity and expanding biopharma sectors. The region offers large-scale manufacturing capabilities with integrated facilities and cost efficiency. Latin American CDMOs face challenges due to inconsistent regulations, though regional collaborations are pushing for harmonization. The region benefits from geographical proximity to North America and a cost-effective labor force, although infrastructural shortcomings have limited rapid expansion. In the Middle East and Africa, CDMOs are primarily engaged in producing intermediates for generics and essential medications, mostly targeting local markets and nearby regions. Its strategic location between Europe and Asia enhances its relevance in global supply chains, giving the region potential to grow into a critical link in pharmaceutical logistics and production networks. Major Players Raghava Life Sciences Pvt LTD., Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Thermo Fisher Scientific, Cambrex Corporation, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the major competitors of the global pharmaceutical intermediate CDMO market.

目錄 Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ................................................... 18 1.1 MARKET OVERVIEW: ................... 19 1.2 MARKET SEGMENTATION ......... 19 1.3 COMPETITIVE LANDSCAPE ........ 19 1.4 FUTURE OUTLOOK ......................... 20 2 MARKET INTRODUCTION ............................................... 22 2.1 DEFINITION ...................................... 22 2.2 SCOPE OF THE STUDY .................. 22 2.3 RESEARCH OBJECTIVE ................ 22 2.4 MARKET STRUCTURE .................. 23 3 RESEARCH METHODOLOGY .......................................... 24 3.1 OVERVIEW ........................................ 24 3.2 DATA FLOW ...................................... 26 3.2.1 Data Mining Process ........... 26 3.3 PURCHASED DATABASE: ............. 27 3.4 SECONDARY SOURCES: ................ 28 3.4.1 Secondary Research Data Flow: ......................................................... 29 3.5 PRIMARY RESEARCH: ................... 30 3.5.1 Primary Research DATA FLOW: ......................................................... 31 3.5.2 Primary Research: Number of Interviews conducted ........................... 32 3.5.3 Primary Research: Regional Coverage ................................................ 32 3.6 APPROACHES FOR MARKET END USER ESTIMATION: ................. 33 3.6.1 Revenue Analysis Approach .............................................................. 33 3.6.2 Data forecasting ................. 34 3.6.3 Data Forecasting Technique .............................................................. 34 3.7 DATA MODELING ............................ 35 3.7.1 microeconomic factor analysis: ......................................................... 35 3.7.2 Data modeling: ................... 36 3.8 TEAMS AND ANALYST CONTRIBUTION ............................................. 37 4 MARKET DYNAMICS ........................................................ 39 4.1 INTRODUCTION ............................... 39 4.2 DRIVERS ............................................. 40 4.2.1 Increasing Outsourcing by Pharmaceutical Companies ....................... 40 4.2.2 Rising Demand for Generic Drugs and Biosimilars .............................. 40 4.2.3 Technological Advancements in Intermediate Synthesis ..................... 40 4.2.4 Growing Complexity of Drug Molecules .............................................. 40 4.2.5 Expansion in Emerging Markets ......................................................... 40 4.3 RESTRAINTS .................................... 42 4.3.1 Stringent Regulatory Compliance and Complex Approval Processes .... 42 4.3.2 High Operational and Capital Expenditure Costs ................................. 42 4.3.3 Property (IP) Risks and Confidentiality Concerns ................................ 42 4.3.4 Supply Chain Disruptions and Raw Material Shortages ........................ 42 4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry ...... 42 4.4 OPPORTUNITY ................................. 44 4.4.1 Strategic Partnerships with Biotech Firms .......................................... 44 4.4.2 Focus on Personalized Medicine Solutions ........................................ 44 4.5 IMPACT ANALYSIS OF COVID – 19 ......................................................... 45 5 MARKET FACTOR ANALYSIS .......................................... 46 5.1 SUPPLY CHAIN ANALYSIS ......... 46 5.1.1 Raw Material Sourcing & Procurement ............................................... 46 5.1.2 Research, Development, & Process Optimization ................................ 46 5.1.3 Manufacturing & Quality Control ........................................................ 47 5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery .... 47 5.2 PORTER’S FIVE FORCES MODEL ............................................................. 48 5.2.1 Threat of New Entrants (Low to Moderate) ......................................... 48 5.2.2 Bargaining Power of Suppliers (Moderate) ......................................... 48 5.2.3 Threat of Substitutes (Low to Moderate) ............................................ 49 5.2.4 Bargaining Power of Buyers (High) .................................................... 49 5.2.5 Intensity of Rivalry (High) .... 49 6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE .... 51 6.1 INTRODUCTION ............................... 51 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS) .......................... 52 6.3 EXCIPIENTS & ADDITIVES .......... 52 7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE .................... 53 7.1 INTRODUCTION ............................... 53 7.2 GENERIC DRUGS .............................. 54 7.3 BRANDED DRUGS ............................ 54 8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION ................. 55 8.1 INTRODUCTION ............................... 55 8.2 ONCOLOGY ........................................ 56 8.3 CARDIOVASCULAR DISEASES ... 56 8.4 CNS & NEUROLOGICAL DISORDERS ........................................................ 56 8.5 INFECTIOUS DISEASES ................. 57 8.6 OTHERS .............................................. 57 9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION ........................... 58 9.1 GLOBAL .............................................. 58 9.2 NORTH AMERICA ........................... 59 9.2.1 USA ................................... 63 9.2.2 CANADA ............................ 64 9.3 EUROPE .............................................. 65 9.3.1 united kingdom................... 69 9.3.2 germany ............................. 71 9.3.3 france ................................ 72 9.3.4 italy ................................... 73 9.3.5 spain ................................. 74 9.3.6 RUSSIA .............................. 75 9.3.7 rest of europe ..................... 76 9.4 ASIA PACIFIC ................................... 77 9.4.1 china.................................. 82 9.4.2 South Korea ....................... 83 9.4.3 indiA .................................. 84 9.4.4 Japan ................................ 85 9.4.5 indonesia ........................... 86 9.4.6 malaysia ............................ 87 9.4.7 thailand .............................. 88 9.4.8 rest of asia pacific .............. 89 9.5 SOUTH AMERICA ........................... 90 9.5.1 Mexico ............................... 95 9.5.2 Brazil ................................. 96 9.5.3 argentina............................ 97 9.5.4 rest of south america .......... 98 9.6 MIDDEL EAST AND AFRICA ........ 99 9.6.1 gcc countries ..................... 105 9.6.2 south africa ........................ 106 9.6.3 rest of middle east & africa ............................................................... 107 10 COMPETITIVE LANDSCAPE ............................................ 108 10.1 INTRODUCTION ............................... 108 10.2 MARKET SHARE ANALYSIS, 2024SS .................................................... 109 10.3 COMPETITOR DASHBOARD......... 110 11 COMPANY PROFILES ...................................................... 111 11.1 RAGHAVA LIFE SCIENCES PVT LTD ...................................................... 111 11.1.1 COMPANY OVERVIEW ......... 111 11.1.2 Key Development ................ 112 11.1.3 SWOT ANALYSIS ................ 112 11.1.4 Key Strategy ....................... 113 11.2 ACTYLIS ............................................. 114 11.2.1 COMPANY OVERVIEW ......... 114 11.2.2 PRODUCT OFFERED ............ 115 11.2.3 Key Development ................ 115 11.2.4 SWOT ANALYSIS ................ 116 11.2.5 Key Strategy ....................... 116 11.3 CHIRACON GMBH ........................... 117 11.3.1 COMPANY OVERVIEW ......... 117 11.3.2 PRODUCT OFFERED ............ 118 11.3.3 SWOT ANALYSIS ................ 118 11.3.4 Key Strategy ....................... 119 11.4 CODEXIS, INC. ................................... 120 11.4.1 COMPANY OVERVIEW ......... 120 11.4.2 PRODUCT OFFERED ............ 121 11.4.3 Key Development ................ 121 11.4.4 SWOT ANALYSIS ................ 122 11.4.5 financial analysis ................ 123 11.4.6 Key Strategy ....................... 123 11.5 ARKEMA S.A. ................................... 124 11.5.1 COMPANY OVERVIEW ......... 124 11.5.2 PRODUCT OFFERED ............ 125 11.5.3 SWOT ANALYSIS ................ 125 11.5.4 financial analysis ................ 126 11.5.5 Key Strategy ....................... 126 11.6 LONZA GROUP AG ........................... 127 11.6.1 COMPANY OVERVIEW ......... 127 11.6.2 PRODUCT OFFERED ............ 128 11.6.3 Key Development ................ 128 11.6.4 SWOT ANALYSIS ................ 129 11.6.5 financial analysis ................ 130 11.6.6 Key Strategy ....................... 130 11.7 THERMO FISHER SCIENTIFIC (PATHEON) .......................................... 131 11.7.1 COMPANY OVERVIEW ......... 131 11.7.2 PRODUCT OFFERED ............ 132 11.7.3 Key Development ................ 132 11.7.4 SWOT ANALYSIS ................ 133 11.7.5 financial analysis ................ 134 11.7.6 Key Strategy ....................... 134 11.8 CAMBREX CORPORATION ........... 135 11.8.1 COMPANY OVERVIEW ......... 135 11.8.2 PRODUCT OFFERED ............ 136 11.8.3 Key Development ................ 136 11.8.4 SWOT ANALYSIS ................ 137 11.8.5 Key Strategy ....................... 137 11.9 CATALENT, INC. .............................. 138 11.9.1 COMPANY OVERVIEW ......... 138 11.9.2 PRODUCT OFFERED ............ 139 11.9.3 Key Development ................ 139 11.9.4 SWOT ANALYSIS ................ 140 11.9.5 financial analysis ................ 141 11.9.6 Key Strategy ....................... 141 11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD ............................ 142 11.10.1 COMPANY OVERVIEW ......... 142 11.10.2 PRODUCT OFFERED ............ 143 11.10.3 Key Development ................ 143 11.10.4 SWOT ANALYSIS ................ 144 11.10.5 financial analysis ................ 145 11.10.6 Key Strategy ....................... 145

圖表清單 List of Tables & Figures

LIST OF TABLES TABLE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 51 TABLE 2 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 53 TABLE 3 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 55 TABLE 4 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2019-2035 (USD MILLION) 58 TABLE 5 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 60 TABLE 6 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 60 TABLE 7 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 61 TABLE 8 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 62 TABLE 9 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 63 TABLE 10 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 63 TABLE 11 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 63 TABLE 12 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 64 TABLE 13 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 64 TABLE 14 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 64 TABLE 15 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 66 TABLE 16 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 67 TABLE 17 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 67 TABLE 18 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 68 TABLE 19 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 69 TABLE 20 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 69 TABLE 21 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 70 TABLE 22 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 71 TABLE 23 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 71 TABLE 24 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 71 TABLE 25 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 72 TABLE 26 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 72 TABLE 27 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 72 TABLE 28 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 73 TABLE 29 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 73 TABLE 30 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 73 TABLE 31 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 74 TABLE 32 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 74 TABLE 33 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 74 TABLE 34 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 75 TABLE 35 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 75 TABLE 36 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 75 TABLE 37 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 76 TABLE 38 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 76 TABLE 39 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 76 TABLE 40 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 78 TABLE 41 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 79 TABLE 42 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 80 TABLE 43 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 81 TABLE 44 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 82 TABLE 45 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 82 TABLE 46 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 82 TABLE 47 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 83 TABLE 48 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 83 TABLE 49 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 83 TABLE 50 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 84 TABLE 51 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 84 TABLE 52 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 84 TABLE 53 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 85 TABLE 54 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 85 TABLE 55 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 85 TABLE 56 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 86 TABLE 57 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 86 TABLE 58 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 86 TABLE 59 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 87 TABLE 60 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 87 TABLE 61 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 87 TABLE 62 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 88 TABLE 63 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 88 TABLE 64 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 88 TABLE 65 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 89 TABLE 66 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 89 TABLE 67 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 89 TABLE 68 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO, BY COUNTRY, 2019-2035 (USD MILLION) 91 TABLE 69 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 91 TABLE 70 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 92 TABLE 71 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 93 TABLE 72 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 95 TABLE 73 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 95 TABLE 74 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 95 TABLE 75 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 96 TABLE 76 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 96 TABLE 77 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 96 TABLE 78 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 97 TABLE 79 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 97 TABLE 80 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 97 TABLE 81 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 98 TABLE 82 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 98 TABLE 83 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 98 TABLE 84 MIDDEL EAST AND AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 100 TABLE 85 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 101 TABLE 86 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 102 TABLE 87 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 103 TABLE 88 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 105 TABLE 89 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 105 TABLE 90 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 105 TABLE 91 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 106 TABLE 92 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 106 TABLE 93 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 106 TABLE 94 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 107 TABLE 95 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 107 TABLE 96 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 107 TABLE 97 RAGHAVA LIFE SCIENCES PVT LTD: PRODUCT OFFERED 112 TABLE 98 ACTYLIS: PRODUCT OFFERED 115 TABLE 99 ACTYLIS: PRODUCT OFFERED 115 TABLE 100 CHIRACON GMBH: PRODUCT OFFERED 118 TABLE 101 CODEXIS, INC.: PRODUCT OFFERED 121 TABLE 102 CODEXIS, INC.: PRODUCT OFFERED 121 TABLE 103 ARKEMA S.A.: PRODUCT OFFERED 125 TABLE 104 LONZA GROUP AG: PRODUCT OFFERED 128 TABLE 105 LONZA GROUP AG: PRODUCT OFFERED 128 TABLE 106 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED 132 TABLE 107 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED 132 TABLE 108 CAMBREX CORPORATION: PRODUCT OFFERED 136 TABLE 109 CAMBREX CORPORATION: PRODUCT OFFERED 136 TABLE 110 CATALENT, INC.: PRODUCT OFFERED 139 TABLE 111 CATALENT, INC.: PRODUCT OFFERED 139 TABLE 112 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED 143 TABLE 113 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED 143 LIST OF FIGURES FIGURE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKETSEGMENT 23 FIGURE 2 DRIVER IMPACT ANALYSIS (2018-2035) 41 FIGURE 3 RESTRAINT IMPACT ANALYSIS (2018-2035) 43 FIGURE 4 SUPPLY CHAIN ANALYSIS 46 FIGURE 5 PORTER’S FIVE FORCES MODEL: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET 48 FIGURE 6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2024 (% SHARE) 51 FIGURE 7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2024 (% SHARE) 53 FIGURE 8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2024 (% SHARE) 55 FIGURE 9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2024 (% SHARE) 58 FIGURE 10 NORTH AMERICAN MARKET: SWOT ANALYSIS 59 FIGURE 11 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 60 FIGURE 12 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 61 FIGURE 13 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 61 FIGURE 14 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 62 FIGURE 15 EUROPE MARKET: SWOT ANALYSIS 65 FIGURE 16 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 66 FIGURE 17 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 67 FIGURE 18 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 68 FIGURE 19 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 69 FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS 77 FIGURE 21 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 78 FIGURE 22 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 79 FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 80 FIGURE 24 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 81 FIGURE 25 SOUTH AMERICA MARKET: SWOT ANALYSIS 90 FIGURE 26 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 91 FIGURE 27 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 92 FIGURE 28 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 93 FIGURE 29 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 94 FIGURE 30 MIDDEL EAST AND AFRICA: SWOT ANALYSIS 99 FIGURE 31 MIDDEL EAST AND AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 100 FIGURE 32 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 101 FIGURE 33 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 102 FIGURE 34 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 103 FIGURE 35 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 104 FIGURE 36 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET: COMPETITIVE ANALSIS, 2024 109 FIGURE 37 COMPETITOR DASHBOARD: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET 110 FIGURE 38 RAGHAVA LIFE SCIENCES PVT LTD: SWOT ANALYSIS 112 FIGURE 39 ACTYLIS: SWOT ANALYSIS 116 FIGURE 40 CHIRACON GMBH: SWOT ANALYSIS 118 FIGURE 41 CODEXIS, INC.: SWOT ANALYSIS 122 FIGURE 42 ARKEMA S.A.: SWOT ANALYSIS 125 FIGURE 43 LONZA GROUP AG: SWOT ANALYSIS 129 FIGURE 44 THERMO FISHER SCIENTIFIC (PATHEON): SWOT ANALYSIS 133 FIGURE 45 CAMBREX CORPORATION: SWOT ANALYSIS 137 FIGURE 46 CATALENT, INC: SWOT ANALYSIS 140 FIGURE 47 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: SWOT ANALYSIS 144

Single User Price	$4,950 USD
Multi User Licence (up to 10 users)	$5,950 USD
Enterprisewide Price (Global Site License)	$7,250 USD

授權報價

報告摘要

提及公司

同分類最新報告（醫療與生命科學）